

(19)



Europäisches Patentamt  
European Patent Office  
Office européen des brevets



(11)

**EP 1 481 083 B1**

(12)

**EUROPEAN PATENT SPECIFICATION**

(45) Date of publication and mention  
of the grant of the patent:

**20.12.2006 Bulletin 2006/51**

(51) Int Cl.:

**C12Q 1/68** <sup>(2006.01)</sup> **C07K 17/00** <sup>(2006.01)</sup>  
**C07K 14/02** <sup>(2006.01)</sup> **G01N 27/26** <sup>(2006.01)</sup>  
**B01J 19/00** <sup>(2006.01)</sup>

(21) Application number: **03702748.9**

(86) International application number:

**PCT/GB2003/000613**

(22) Date of filing: **11.02.2003**

(87) International publication number:

**WO 2003/074731 (12.09.2003 Gazette 2003/37)**

**(54) DETECTION OF NUCLEIC ACIDS**

BESTIMMUNG VON NUKLEINSÄUREN

DETECTION D'ACIDES NUCLEIQUES

(84) Designated Contracting States:

**AT BE BG CH CY CZ DE DK EE ES FI FR GB GR  
HU IE IT LI LU MC NL PT SE SI SK TR**

(30) Priority: **07.03.2002 GB 0205455**

(43) Date of publication of application:

**01.12.2004 Bulletin 2004/49**

(73) Proprietor: **Atlas Genetics Limited**

**Trowbridge  
Wiltshire BA14 9ED (GB)**

(72) Inventors:

- **BRAVEN, Helen**  
**Melksham SN12 8LH (GB)**
- **KEAY, Russell**  
**Melksham SN12 8LH (GB)**

(74) Representative: **Brady, Paul Andrew**

**Abel & Imray  
20 Red Lion Street  
London WC1R 4PQ (GB)**

(56) References cited:

- **UMEK ET AL: "Electronic detection of nucleic acids" JOURNAL OF MOLECULAR DIAGNOSTICS, vol. 3, no. 2, May 2001 (2001-05), pages 74-84, XP002260324**
- **YU ET AL: "Electronic detection of single-base mismatches in DNA with ferrocene-modified probes" JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 123, 2001, pages 11155-11161, XP002260325**
- **IHARA ET AL: "Ferrocene-oligonucleotide conjugates for electrochemical probing of DNA" NUCLEIC ACIDS RESEARCH, vol. 24, no. 21, - 1996 pages 4273-4280, XP002260326**
- **BEILSTEIN ET AL: "Synthesis and characterization of ferrocene-labeled oligodeoxynucleotides" JOURNAL OF ORGANOMETALLIC CHEMISTRY, vol. 637-639, 3 December 2001 (2001-12-03), pages 398-406, XP004323925 ISSN: 0022-328X**

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

**EP 1 481 083 B1**

**Description**Field of the invention

- 5 **[0001]** The invention relates to a method of probing for a nucleic acid, whereby the probe is labelled with an electrochemically active marker, and an apparatus adapted for this method.

Background of the invention

- 10 **[0002]** The detection of specific DNA or RNA sequences is important for a wide range of applications within food, environmental and clinical diagnostics industries, and in the genomic, academic, pharmaceutical and pharmacogenetic research sectors. Detection methodologies should ideally be sensitive, sequence-specific, relatively rapid, low cost, accurate and suitable for routine use and/or automation. Furthermore they should ideally be capable of being integrated with existing DNA amplification methodologies for example the polymerase chain reaction (PCR) and other nucleic  
15 amplification methodologies.

- [0003]** In addition to nucleic acid detection methods based on or integrated with amplification techniques such as PCR, there are also known techniques for sequence specific nucleic acid detection which are based on specific binding of a probe to a target which need not necessarily have been previously amplified. Southern and Northern blotting are known examples of such techniques. Techniques that do not include an amplification stage must usually be highly  
20 sensitive in order to detect a signal. Typically autoradiography or chemiluminescence based techniques are used to produce the required sensitivity.

**[0004]** Southern and Northern blotting require the binding of the target nucleic acid to a membrane substrate. This requirement is disadvantageous because it is time consuming and poorly suited to automation.

- [0005]** Amplification-based DNA detection methods normally utilize a range of fluorescence chemistries or radioactive labels. Frequently, target DNA to be analysed is amplified enzymically e.g. by PCR, and then visualized using a fluorescent DNA binding dye to stain DNA size-separated by gel electrophoresis. Alternative methods that do not require gel electrophoresis have been developed. These frequently allow real-time detection of DNA amplification with non-sequence-specific fluorescent dyes e.g. SYBR Green or ethidium bromide. Assays have also been developed that integrate DNA amplification by PCR with fluorescence-based detection using an expanding variety of fluorescently labelled oligonucleotide probes that hybridise to specific DNA sequences. A number of assays have been developed that utilize the  
30 nuclease activity of a DNA polymerase. Examples of commercially available nuclease assays include Invader (trade mark-Third Wave Technologies), Readit (trade mark- Promega) and TaqMan (trade mark- Applied Biosystems). In TaqMan assays described for example in patents US 5,487,972, US 5,538,848 and US 5,804,375 a hybridisation oligonucleotide is digested by the inherent 5' nuclease activity of *Taq* polymerase concomitant to primer extension by the polymerase activity of *Taq*.  
35

- [0006]** The application of electrochemistry to DNA detection offers potential advantages over other detection systems in terms of sensitivity and simplicity. Their portability, robustness, ease of miniaturization and potential for high volume manufacturing makes apparatus for electrochemical methods especially suitable for clinical, food and environmental diagnostics.

- 40 **[0007]** The major focus for electrochemically-based gene probes has been on electrode-linked hybridisation techniques. Typically a capture probe (oligonucleotide or peptide nucleic acid) is immobilized on an electrode surface and it extracts the complementary target nucleic acid from a complex mixture of nucleic acids. The hybridisation event is transduced into a measurable electronic signal using either a redox-active hybridisation indicator (e.g. a ruthenium or cobalt salt), a redox-active indicator brought into contact with the target using a secondary probe, or by the direct  
45 measurement of changes in electrode capacitance caused by changes in the physical characteristics of the interface between the electrode and solution as a result of hybridisation. Frequently, these systems require prior amplification, e.g. by PCR, of the target sequence in order to achieve sufficient sensitivity.

- [0008]** Methods for detecting nucleic acid binding proteins include nuclease protection assays. In such assays a nucleic acid probe is mixed in solution with a putative nucleic acid binding protein. Under appropriate conditions nucleic acid binding proteins can be made to bind to the nucleic acid sequence present in the probe. Following putative binding any unbound probe or region of probe can be digested by a suitable nuclease. Bound nucleic acid probe will be protected from nuclease digestion because the bound protein will sterically hinder the nuclease. Digested and undigested nucleic acid probe are then separated, for example by gel filtration, gel-electrophoresis or by encouraging undigested nucleic acid to bind to a membrane or other substrate, and quantified. Typically the probe is labelled with a radioactive isotope  
50 in order that it and its breakdown products can be quantified. There are drawbacks to using radioisotopes including problems with radioactive decay reducing the shelf life of reagents and occupational health and environmental concerns.

- [0009]** Nucleic acid probes suitable for detecting nucleic acid binding proteins include nucleic acids substantially of the sequence known to bind nucleic binding proteins *in vivo*. Additionally suitable probes for detecting nucleic acid

binding proteins include aptamers which are nucleic acids evolved *in vitro* to perform a specific function (see for example Brody and Gold, Reviews in Molecular Biology 9 (1999) 324-329, Jäschke *et al*, Synlett 6 (1999) 825-833 and Griffith & Tawfik, Current Opinion in Biotechnology 11 (2000) 338-353 for details). Aptamers may be produced to bind to potentially any specific protein not just proteins ordinarily considered to be nucleic acid binding protein.

**[0010]** The use of the term "hybridise" in the context of nucleic acids in this specification will be understood to mean specific binding of a first nucleic acid to a second nucleic acid of complementary sequence. It will also be understood that in order for hybridisation to occur the complementarity of nucleic acid sequences is not required to be total. Hybridisation includes complementary binding that includes base mis-match to the extent that such mis-match shall not materially reduce the efficiency of the methods described.

**[0011]** The invention provides a method of probing for a nucleic acid comprising contacting a nucleic acid solution with an oligonucleotide probe labelled with an electrochemically active marker, providing conditions at which the probe is able to hybridise with any complementary (target) sequence which may be present in the nucleic acid solution, selectively degrading either hybridised or unhybridised nucleic acid probe, and electrochemically determining information relating to the electrochemically active marker. The information relating to the marker is expediently used to derive information concerning the presence or absence of at least one nucleic acid species. Preferably the electrochemical techniques are used to quantify relative proportions of degraded and non-degraded probe. As used herein, the term degrade includes degradation as a result of enzyme activity, for example by digestion.

**[0012]** A number of methods of selectively degrading either hybridised or unhybridised nucleic acid probe are available. These include enzymatic methods or chemical treatments. Enzymes may be used to degrade a nucleic acid probe by digestion that results in cleavage of a phosphor-ester bond or cleavage of a saccharide or glycosidic bond.

**[0013]** S1 nuclease isolated from *Aspergillus oryzae* or another suitable source, or an enzyme having a similar specificity may be used to selectively digest unhybridised nucleic acid. The 5' nuclease activity of *Taq* polymerase or a similar enzyme may be used to digest a nucleic acid probe which has hybridised at a position on the target between a pair of PCR primers. In that case the probe would be digested concomitant to primer extension.

**[0014]** The Invader (trade mark) system of Third Wave Technologies Inc. (see US 5,846,717, US 5,837,450, US 5,795,763 and US 5,614,402) provides a fluorogenic nucleic acid detection system that may be adapted for use with an alternative embodiment of the electrochemical detection system of the present invention as illustrated in Fig. 14a. Briefly, two short oligonucleotide probes are allowed to hybridise with the target nucleic acid. The probes are so designed that, whilst both are able to hybridise for at least part of their length to form a nucleic acid duplex, there is a region of sequence overlap between the two probes. This produces a specific structure which is recognized by an enzyme which cleaves one of the probes to release a "5' flap" from the overlap region. A suitable enzyme is the flap endonuclease (FEN1) from *Archaeoglobus fulgidus*, sold under the Trademark "Cleavase VIII". An electrochemically active marker may be linked to the primer which yields the 5' flap, preferably at or towards the 5' end of that primer. The presence of the 5' flap in the reaction mixture may be detected by electrochemical techniques. Particularly, the electrochemically labelled 5' flap may be discriminated from the electrochemically labelled primer by virtue of the different length oligonucleotide portion of each respective molecule.

**[0015]** Alternatively and as illustrated in Fig 14b, the 5' flap is not required to be linked to an electrochemically active marker. The release of the 5' flap is detected by an oligonucleotide recognition cassette which forms a nucleic acid triplex region which is also recognised and cleaved by cleavase enzyme. An electrochemically active marker may be linked to the recognition cassette so that cleavage of the recognition cassette results in the electrochemically active marker being linked to a fragment of the recognition cassette as opposed to the full length recognition cassette. The electrochemically labelled recognition cassette fragment may be discriminated from the electrochemically labelled full length recognition cassette by virtue of the different length oligonucleotide portion of each respective molecule.

**[0016]** The present invention is based on the observation that an electrochemically active marker such as metallocene exhibits different electrochemical characteristics depending on whether or not it is attached to a nucleotide, whether or not that nucleotide is incorporated into oligonucleotide or not, and the length of any such oligonucleotide.

**[0017]** The size and characteristics of a molecule to which an electrochemically active marker is attached may influence the perceived characteristics of the electrochemical marker for example, by influencing its rate of migration by diffusion or in response to an electric field.

**[0018]** The electrochemical activity of a marker may also be influenced by steric effects resulting from the presence of the molecule to which it is linked. For example, steric hindrance may prevent the marker from approaching an electrode and accepting or donating electrons.

**[0019]** If the marker is attached to an oligonucleotide then the secondary structure of the oligonucleotide (as largely determined by primary sequence) may influence the physical properties of that marker. For example, if the marker is attached to an oligonucleotide that contains self-complementary primary sequence then the resultant stem and loop secondary structure may sterically hinder the electrochemically active marker and reduce the signal obtained by voltammetry. It will be understood that digestion of the oligonucleotide may destroy or release the stem and loop structure and reduce or abolish its influence on the marker.

**[0020]** It will also be apparent that because the secondary structure of oligonucleotides is dependent on temperature, the effects which an oligonucleotide have on an electrochemically active marker vary with temperature.

**[0021]** A person skilled in the art is able to select an appropriate temperature at which to carry out the electrochemical technique of the invention in order to achieve an optimum signal to background noise ratio for the technique. If the technique is incorporated into a PCR reaction or other technique for which a thermal cycling apparatus is used, measurement at a desired temperature may simply be made at an appropriate point in the PCR temperature regime.

**[0022]** In one form of the method according to the invention 5' nuclease digestion of the probe labelled with an electrochemically active marker takes place concomitant to PCR primer extension. It will be apparent that such method includes a real time PCR method in which the electrochemical activity of the solution is automatically measured during or following each PCR cycle. The more target that is present in the sample the more primer extension and probe digestion is likely to take place. The accumulated digested probe will be distinguished from undigested probe due to its different electrochemical activity. As discussed above, the temperature (PCR phase) at which measurements are made may influence the quality of signal obtained.

**[0023]** For simplicity, the present invention has largely been described in terms of detecting a single nucleic acid species. It will, however, be appreciated that the invention includes a "multiplex" system by which the methods and apparatus disclosed may be used to detect more than one nucleic acid species simultaneously. Multiplex systems have the general advantages that they enable control experiments to be carried out simultaneously and under the same conditions as a test experiment or that they enable several analyses to be carried out simultaneously and under the same conditions. The use of multiplex systems thus brings about savings of reagents and time. An example of such a multiplex system is the use of oligonucleotide probes which are complementary to two or more different targets. Those probes might be distinguished from each other by being labelled with electrochemically active markers having different redox characteristics and therefore being separately identifiable by any suitable electrochemical technique for example, differential pulse voltammetry. In order to be suitable for use in a multiplex experiment, two (or more) markers should have redox characteristics that are sufficiently different from each other to enable the two (or more) markers to be analysed in a resolvable fashion. For example, if differential pulse voltammetry is to be used, the voltammogram traces for the two (or more) markers should have peaks at voltages that are resolvable from each other. Preferably two different markers are used. The invention provides novel electrochemical markers, which may be used in a multiplex system. The provision of novel markers increases the range of markers available and therefore makes the development of multiplex systems feasible.





**[0024]** The labelled oligonucleotides used in accordance with a first aspect of the invention are capable of producing a distinct or enhanced electrochemical signal due to the release of ferrocenylated mononucleotide, dinucleotide or oligonucleotide from a hybridisation oligonucleotide in a sequence-dependent nuclease assay. Those assays depend on a nuclease activity to cause a change to the probe such that a novel or enhanced signal is produced on recognition of a specific nucleic acid sequence.





**[0025]** If desired, the electrochemical detection step may be carried out using one or more electrodes covered by a membrane which is able selectively to exclude molecules based on one or more characteristics, for example, characteristics selected from size, charge and hydrophobicity. That may assist in eliminating background current arising from, for example, charged nucleic acid or undigested labelled oligonucleotide.

**[0026]** Suitable electrochemically active markers include those comprising metallo-carbocyclic pi complexes, that is organic complexes with partially or fully delocalised pi electrons. Suitable markers include those comprising sandwich compounds in which two carbocyclic rings are parallel, and also bent sandwiches (angular compounds) and monocyclopentadienyls. Preferably, the electrochemically active markers are metallocenyl labels. More preferably they are ferrocenyl labels.


**[0027]** Ferrocenyl and metallocenyl labels used in the probes according to the invention may advantageously be *N*-substituted ferrocene or metallocene carboxamides. The ferrocene or metallocene ring, which constitutes the labelling moiety, may be unsubstituted. If desired, the ferrocene or metallocene ring may be substituted by one or more substituents, the nature and location of which are selected so as to influence in a desired manner the redox characteristics of the ferrocene or metallocene moiety. The ferrocene or metallocene ring may additionally or instead be substituted by any ring substituents that do not materially reduce the electrochemical sensitivity of the label. The ferrocene or metallocene carboxamide moiety may be linked via the carboxamide nitrogen to the nucleotide or oligonucleotide. Linkage to the nucleotide or oligonucleotide is preferably via a phosphate group or via the base of the nucleotide. Both methods of linkage permit the label to be attached via any nucleotide along the length of the oligonucleotide. However if linkage is via a phosphate group it is advantageously via a 3' or 5' terminal phosphate group so as to minimise the likelihood that such linkage will sterically hinder Watson-Crick hybridisation of the oligonucleotide or affect nuclease activity. Linkage via a region of the base not involved in Watson-Crick base pairing is predicted to be less disruptive of such base pairing. Therefore linkage via the base may be more suitable for labelling at non-terminal oligonucleotide sites. The label oligonucleotide may have a linker moiety between the oligonucleotide and the labelling moiety. Preferably, the labelled oligonucleotides have a ferrocenyl labelling moiety which is linked to the oligonucleotide by a linker moiety.

[0028] There may be used any suitable linker moiety. Suitable linker moieties may comprise an aliphatic chain which may be linear or branched, and saturated or unsaturated. Advantageously, the linker moiety is a linear or branched aliphatic chain having from 4 to 20 carbon atoms, and preferably from 6 to 16, especially from 8 to 14 atoms, especially 12 carbon atoms. The alkylene chains may be substituted by any substituent or may be interrupted by any atom or moiety provided that any such substituent, atom or moiety does not materially reduce the electrochemical sensitivity of the label. Illustrative of the ferrocenyl labels which may be used in accordance with the invention are those in Formulae I to III. Molecules of formula Ia to IIIa are oligonucleotides labelled with the corresponding ferrocenyl labels. Formula IV is illustrative of a ferrocenyl label which may be attached via a nucleotide base, the amino-modified thymine base being included in Formula IV for the purposes of illustration.






55 [0029] The ferrocene labelled probes may be made by any suitable method. By way of example, the oligonucleotide may be an oligonucleotide modified by introduction of a radical having a terminal amino group. Illustrative of such amino-modified nucleotides is the modified nucleotide of Formula V. The ferrocene may then be incorporated by reaction of the amino-modified nucleotide with the *N*-hydroxy-succinimide ester of ferrocene carboxylic acid (Formula VI) to obtain ferrocene labelled oligonucleotide.




V




VI

**[0030]** In an alternative method, ferrocene labelled oligonucleotides may be prepared by addition of the ferrocene moiety during solid phase oligonucleotide synthesis. Ferrocene labels can be introduced into an oligonucleotide during solid phase synthesis by two general methods: Firstly, addition of the oligonucleotide at the 3' end of the oligonucleotide requires the use of a suitable resin. Such a resin is labelled with a ferrocene derivative. Addition of ferrocene at an internal site, or at the 5' end of an oligonucleotide requires the use of a coupling reagent suitable for coupling with a solid support bound oligonucleotide, for example a ferrocenyl derivative phosphoramidite, for example as shown as formula IX or X.




IX



X

**[0031]** Further disclosed is an alternative electrochemically active marker, label or labelled moiety, such as a compound of formula XI,



Wherein

- Mc is a metallocenyl group in which each ring may independently be substituted or unsubstituted,
- the metallocenyl group comprises a metal ion M selected from the group consisting of iron, chromium, cobalt,

osmium, ruthenium, nickel or titanium,

- R' is H or lower alkyl,
- X is either NR' or O,
- Ar is a substituted or unsubstituted aryl group,
- n is 0 or 1,
- L is a linker group,
- m is 0 or 1, and
- R represents a moiety to be labelled or R is a moiety comprising a leaving group.

**[0032]** The Me group may be substituted by one or more groups selected lower alkyl (for example C<sub>1</sub> to C<sub>4</sub> alkyl), lower alkyl substituted with a hydroxy, halo, cyano, oxo, amino, ester amido or a further metallocene group, lower alkenyl, lower alkenyl substituted with a hydroxy, halo, cyano, oxo, amino, ester, amido or a further metallocene group, aryl, aryl substituted with a hydroxy, halo, cyano, oxo, amino, ester, amido or a further metallocene group. The further metallocene group may be substituted in the same way as the Mc group with the exception that the total number Mc groups in the molecule of the invention preferably does not exceed four. Preferably, the Mc group is unsubstituted.

**[0033]** Preferably, M is an ion selected from iron, osmium or ruthenium. Most preferably, M is an iron ion. When M is an iron ion, Mc is a ferrocene.

**[0034]** Lower alkyl is preferably C1 to C4 alkyl. Preferably, R' is H. Each R' has an identity separate from the other R'.

**[0035]** Preferably X is NH.

**[0036]** The Ar group may be substituted by one or more groups selected lower alkyl (for example C<sub>1</sub> to C<sub>4</sub> alkyl), lower alkyl substituted with a hydroxy, halo, cyano, oxo, amino, ester or amido group, lower alkenyl, lower alkenyl substituted with a hydroxy, halo, cyano, oxo, amino, ester or amido group, aryl or aryl substituted with a hydroxy, halo, cyano, oxo, amino, ester or amido group. Preferably, the Ar group is unsubstituted.

**[0037]** Preferably, n=1. Preferably, m=1.

**[0038]** Suitable linker groups L may comprise an aliphatic chain which may be linear or branched, and saturated or unsaturated. Advantageously, the linker moiety is a linear or branched aliphatic chain having from 4 to 20 carbon atoms, and preferably from 6 to 16, especially from 8 to 14 atoms, more especially 12 carbon atoms. The alkylene chains may be substituted by any substituent or may be interrupted by any atom or moiety provided that any such substituent, atom or moiety does not materially reduce the electrochemical sensitivity of the label.

**[0039]** The compound may comprise more than one metallocene groups. In the compound of the invention, the metallocene group may be substituted by any other electrochemically active marker group. The compound may be one which is electrochemically active or becomes electrochemically active following partial cleavage.

**[0040]** Preferably, the moiety to be labelled is an amino acid, a nucleotide, an oligonucleotide, a polynucleotide, a nucleoside, a sugar, a carbohydrate, a peptide, a protein or a derivative of any of those molecules. In a preferred embodiment, R is a nucleotide or an oligonucleotide. The nucleotide may be selected from adenosine, thymidine, guanosine, cytidine or uridine. Preferably the nucleotide is attached through a group attached to the ribose or deoxyribose group of the nucleotide, for example in the 2', 3' or 5' position. Most preferably, the nucleotide is attached at the 3' or 5' position, for example at the 5' position. Preferably, the attachment at the 2', 3' or 5' position is through an oxygen or a nitrogen atom.

**[0041]** In a further preferred embodiment, R is a group comprising a leaving group, preferably an alkyl or a carbonyl group comprising a leaving group. Amongst alkyl groups there are preferred lower alkyl groups (for example C<sub>1</sub> to C<sub>4</sub> alkyl groups) Amongst leaving groups, there may be mentioned hydroxyl, halides, organic acids and N-hydroxy diacylamines. The leaving group may, for example be chloride, bromide or iodide, acetic acid, a benzoic acid, 2,6 dichlorobenzoic acid, an N-hydroxysuccinamide, a maleimide, iodoacetamide or isothiocyanate. Preferably the leaving group is N-hydroxysuccinamide. The leaving group may be an activatable group suitable for use in a reaction for coupling to a solid-support bound moiety. For example, the leaving group may be a phosphoramidite group.

**[0042]** When R is a group comprising a leaving group the compound is a labeling reagent which may be used to electrochemically label another molecule. The labeling reagent is particularly useful for labeling biologically important molecules for use in either known methods or methods of the invention. Molecules of interest that may be labelled include, but are not limited to - amino acids, nucleotides, nucleosides, sugars, peptides, proteins, oligonucleotides, polynucleotides, carbohydrates and derivatives of any of those molecules.

**[0043]** The labeling reagent may be attached directly or via a linker. The linker may be attached first to the labeling reagent or to the molecule to be labelled. If the linker is first attached to the molecule to be labelled it may comprise a group, for example, an amino or a thiol group, that will assist in the labeling reaction. An amino group is preferred.

**[0044]** If the molecule to be labelled is a nucleotide or an oligonucleotide the labeling is preferably to the 3' or 5' end. The oligonucleotide may be amino-modified to assist with the labeling reaction. Amino-modified oligonucleotides may be synthesized by standard techniques and are available from a wide range of commercial sources for example from Oswel Scientific (Southampton, UK). The amino-modified oligonucleotide may also incorporate a linker motif, for example,





the modification may be the addition of 5' aminoethyl or 3' aminoethyl or a 5'- C12 amino-group. A labelled molecule of interest preferably comprises a linker.

[0045] In the case of an oligonucleotide, the sequence of the oligonucleotide portion of the molecule is preferably such that the molecule is able to hybridize with a complementary target sequence and thus be used as a probe in a molecular biological technique, for example, one of the nucleic acid detection or qualification techniques disclosed in this specification.

[0046] Labelled biological molecules for use in the method of the invention may be electrochemically active in either digested or non-digested states. Ideally the extent of electrochemical activity will vary in dependence on the extent of digestion.

[0047] Formula VIII illustrates a possible mode of attachment of the novel electrochemically active marker to an oligonucleotide. The molecule of formula VIII may be obtained by reacting a 5'-aminoethyl modified oligonucleotide with the molecule shown in formula VII.



[0048] Details of *N*-hydroxysuccinimide ester of 4-(3'-ferrocenylureido)-1-benzoic acid and details of the use of said compound to label oligonucleotides are provided in Examples 7 and 8. It will however be apparent to the skilled person that such a label may be attached to an oligonucleotide at any suitable position and that attachment is not limited to the 5' end of said oligonucleotide. It will also be apparent that attachment of the novel marker need not be via an aminoethyl linker nor need the marker be attached necessarily to an oligonucleotide. There is potential for the novel marker to be used to label other molecules of interest, especially molecules of biological interest such as proteins, carbohydrates and antibodies.

[0049] The disclosed molecules have particular utility in methods according to the invention. Under the conditions set out in table 3, the electrode potential of substituted ferrocene carboxylic acids have an electrode potential in the region of 400mV. On the other hand, substituted metallocene molecules in accordance with the invention have an electrode potential in the region of 150mV. The lower potential is a potential at which the propensity for background impurities to interfere with data collection is much lower. Accordingly, the molecules enable more sensitive readings to be taken. In Figure 23 there are shown voltammograms illustrating the different electrode potentials of a conventional ferrocene derivative (ferrocene carboxylic acid XII) in Figures 23(a) and (b) and 4-(3'-ferrocenylureido)-1-benzoic acid, a ferrocene derivative with a ferrocene moiety as found in molecules of the invention, in Figures 23(c) and (d). As is seen from a comparison of Figures 23(b) and 23(d) the peak for the ferrocene derivative with a ferrocene moiety as disclosed comes at a part of the scanning voltammogram at which the background signal is weak, thus enabling a more sensitive detection of that molecule.

[0050] The invention also provides apparatus arranged to carry out any one or more of the methods disclosed herein. These apparatus comprise both a thermal cyclor and apparatus for voltammetry. Such apparatus may include suitable electrodes, electrochemical cells, apparatus may include suitable electrodes, electrochemical cells, disposable plastic ware and apparatus for detecting, recording, manipulating and displaying results, and in the case of PCR methods,

appropriately programmed or programmable thermal cyclers. Such apparatus may also include apparatus for the optimal design of primers, probes and cycling conditions.

**[0051]** The invention provides apparatus comprising one or more sample receiving regions for receiving one or more samples, means for controlling the temperature of said sample receiving regions and means for measuring the electrochemical properties of said sample. According to one embodiment of the invention, there is provided a thermal cycler which may use conventional means to control sample temperature but into which has been integrated a means for making electrochemical measurements of the samples. Such an apparatus may be manufactured so as to utilize conventional electrode cells (for example those used in examples herein).

**[0052]** Certain illustrative embodiments of the invention will now be described in detail with reference to the accompanying drawings in which:

Fig. 1 is a schematic representation of an electrochemical cell used in differential pulse voltammetry measurements described herein;

Figs. 2a, 2b, 2c and 2d are differential pulse voltammograms of ferrocene labelled BAPR oligonucleotide as described in Example 4(a) below;

Figs. 3a, 3b, 3c and 3d are differential pulse voltammograms of ferrocene labelled BAPR oligonucleotide as described in Example 4(b) below;

Figs. 4a, 4b, 4c and 4d are differential pulse voltammograms of ferrocene labelled T1BAPR oligonucleotide as described in Example 4(c) below;

Figs. 5a, 5b, 5c and 5d are differential pulse voltammograms of ferrocene labelled BAPR oligonucleotide as described in Example 4(d) below;

Figs. 6a, 6b, 6c and 6d are differential pulse voltammograms of ferrocene labelled GSDPR oligonucleotide as described in Example 4(e) below;

Figs. 7a, 7b, 7c and 7d are differential pulse voltammograms of ferrocene labelled MC11PR oligonucleotide as described in Example 4(f) below;

Figs. 8a and 8b are differential pulse voltammograms of unlabelled BAPR oligonucleotide as described in Example 4(g) below;

Figs 9a and 9b are differential pulse voltammograms of control reactions for ferrocene labelled T1BAPR oligonucleotide as described in Example 4(h) below;

Figs. 10a, 10b, 10c and 10d are differential pulse voltammograms of PCR mixture containing labelled BAPR oligonucleotide as described in Example 5(a) below;

Figs. 11a, 11b and 11c are differential pulse voltammograms of another PCR mixture containing ferrocene labelled MC11PR oligonucleotide as described in Example 5(b) below;

Figs. 12a, 12b, 12c and 12d are differential pulse voltammograms of a PCR mixture containing ferrocene labelled T1BAPR oligonucleotide as described in Example 5(c);

Figs. 13a, 13b, 13c and 13d are differential pulse voltammograms of a PCR mixture containing ferrocene labelled GSDPR oligonucleotide as described in Example 5(d);

Fig. 14a and 14b are schematic representations of the Invader fluorogenic nucleic acid detection system adapted for use in a method of the invention;

Fig. 15a illustrates the use of the methods of the invention in a T7 exonuclease assay;

Fig. 15b illustrates the use of the methods of the invention in an assay incorporating a T7 exonuclease digestion of a labelled oligonucleotide probe annealed to PCR products;

Fig. 16a and Fig. 16b are differential pulse voltammograms illustrating T7 exonuclease substrate specificity (Example 9);

Fig. 17a and Fig. 17b are differential pulse voltammograms illustrating T7 exonuclease digestion of PCR product labelled with 5' ferrocenylated primer (Example 10(a));

Fig. 18a to Fig. 20b are differential pulse voltammograms illustrating T7 exonuclease digestion of Taqman (Trade Mark - Applied Biosystems) probe annealed to PCR product (Example 10(b));

Fig. 21a and Fig. 21b are differential pulse voltammograms illustrating PCR amplification with Stoffel fragment (Example 10(c)); and

Fig. 22a and Fig. 22b are differential pulse voltammograms illustrating experiments with no T7 exonuclease (Example 10(d)).

Fig. 23a and Fig. 23b are differential pulse voltammograms illustrating the electrode potential of ferrocene carboxylic acid at 10 $\mu$ M and 1 $\mu$ M concentration respectively and Fig. 23c and

Fig. 23d are differential pulse voltammograms illustrating the electrode potential of 4-(3'-ferrocenylureido)-1-benzoic acid at 10 $\mu$ M and 1 $\mu$ M concentration respectively.

Fig 24 shows differential pulse voltammograms of the products of nuclease digest reactions in which the substrate were (a) the were BAPR oligonucleotide labelled at the 5' end by ferrocene with a 12 carbon spacer moiety (2.5 $\mu$ M)

and MC11w oligonucleotide labelled at the 5' end by 4-(3-ferrocenylureido)-1-benzoic acid with a 12 carbon spacer moiety (1.5 $\mu$ M), (b) BAPR oligonucleotide labelled at the 5' end by ferrocene with a 12 carbon spacer moiety only (2.5 $\mu$ M) and (c) MC11w oligonucleotide labelled at the 5' end by 4-(3-ferrocenylureido)-1-benzoic acid with a 12 carbon spacer moiety only (1.5 $\mu$ M).

[0053] With reference to Fig. 1, an electrochemical cell 1 suitable for use in the cyclic voltammetry experiments described herein comprises a vessel 2, containing a background electrolyte solution 3, which is an aqueous 100mM solution of ammonium acetate. Immersed in the solution 3 is a chamber 4, which receives both the sample to be tested and, immersed therein, a glassy carbon working electrode 5. A gold electrode may alternatively be used. Also immersed in the solution 3 is a counter-electrode 6 of platinum wire and a silver/silver chloride reference electrode 7 immersed in 4M potassium chloride solution, which solutions are in communication with others via a sintered disc.

[0054] With reference to Fig. 15a and Fig 15b, T7 exonuclease (sometimes referred to as T7 gene 6 exonuclease) is a duplex specific 5' to 3' exonuclease. The enzyme digests oligonucleotides annealed to a target region of DNA in order to produce mononucleotide, dinucleotide and shorter oligonucleotide fragments. The substrate specificity of the enzyme is such that oligonucleotide probes labelled with an electrochemical marker such as ferrocene at the 5' end can be digested. Digested ferrocene labelled probes can be detected by electrochemical methods, for example by differential pulse voltammetry. T7 exonuclease is not thermostable, and therefore is not stable under the thermal cycling conditions normally used in PCR.

[0055] T7 exonuclease can be used in PCR based DNA detection in two ways. PCR products labelled at the 5' end with a marker such as ferrocene can be synthesized by using a 5' labelled primer. The T7 exonuclease subsequently added to the PCR mix digests the labelled PCR product. Non-amplified single strand primer will not be digested (Fig. 15a). In the second method, in order to provide sequence specific PCR product detection, an electrochemically labelled probe similar to a Taqman probe (Trade Mark -Applied Biosystems) in that it is designed to hybridized to the target nucleic acid between the primer sequences, is used instead of labelled primers. The probe is introduced into the PCR mix after thermal cycling and allowed to anneal to the target. T7 exonuclease is then added and the probe is digested only if it has formed a duplex by annealing with a complementary PCR product.

[0056] The following Examples illustrate the invention:

#### Materials and methods - Oligonucleotide preparation and assays

[0057] Oligonucleotides were obtained from Sigma Gensosys. All oligonucleotides were obtained desalted and were used without further purification. N,N'-Dimethylformamide (DMF) (99.8% A.C.S. reagent) and zinc acetate dihydrate (99.999%) were obtained from Aldrich.

[0058] Potassium bicarbonate (A.C.S. reagent), potassium carbonate (minimum 99%), ammonium acetate (approximately 98%), magnesium acetate (minimum 99%), ammonium persulfate (electrophoresis reagent), N,N,N',N'-tetramethylethylenediamine (TEMED) and molecular biology grade water were obtained from Sigma.

[0059] NAP10 columns (G25 DNA grade Sephadex trade mark) were obtained from Amersham Biosciences.

[0060] S1 Nuclease, dNTPs and human genomic DNA were obtained from Promega.

[0061] AmpliTaq Gold, with 25 mM magnesium chloride and GeneAmp (trade mark) 10X PCR Gold buffer supplied and AmpliTaq DNA Polymerase, Stoffel Fragment, with 10X Stoffel buffer and 25mM magnesium chloride supplied, was obtained from Applied Biosystems.

[0062] T7 exonuclease was obtained from New England Biolabs.

[0063] Incubations were performed using a PTC-100 Programmable Thermal Controller (MJ Research Inc.). Absorbance measurements at 260nm were performed using a Cary 100 Bio spectrophotometer (Varian Ltd.).

[0064] Polyacrylamide gels were prepared with ProtoGel (National Diagnostics) and stained with SYBR Gold (Molecular Probes Inc.).

[0065] Agarose gels were prepared with SeaKem LE agarose (BioWhittaker Molecular Applications) and stained with ethidium bromide (Aldrich). Gels were electrophoresed in 0.5X Tris/borate/EDTA (TBE) buffer (Sigma). All solutions were prepared with autoclaved deionised water (WaterPro system, Labconco).

#### Oligonucleotide sequences

[0066] The oligonucleotide sequences of the glucose-6-phosphatase and medium chain acyl-CoA dehydrogenase primers and probes were as disclosed in Kunihiro Fujii, Yoichi Matsubara, Jun Akanuma, Kazutoshi Takahashi, Shigeo Kure, Yoichi Suzuki, Masue Imiazumi, Kazuie Iinuma, Osamu Sakatsume, Piero Rinaldo, Kuniaki Narisawa; Human Mutation; 15; 189-196; (2000).

[0067] The oligonucleotide sequence of the beta actin primers and probe were as disclosed in Agnetha M Josefsson, Patrik K E Magnusson, Nathelie Ylitalo, Per Sorensen, Pernilla Qvarforth-Tubbin, Per Kragh Andersen, Mads Melbye,

## EP 1 481 083 B1

Hans-Olov Adami, Ulf B Gyllensten; Lancet; 355; 2189-2193; (2000).

**[0068]** The oligonucleotide sequence of the HFE gene primers and probe were as disclosed in Luis A. Ugozzoli, David Chinn, Keith Hamby, Analytical Biochemistry; 307; 47-53 (2002).

5 ACTB ( $\beta$  actin)

**[0069]**

Probe

10

BAPR: ATG CCC TCC CCC ATG CCA TCC TGC GT  
C9-T1BAPR: T(C9)G CCC TCC CCC ATG CCA TCC TGC GT

(T(C9) = amino modified thymine with C9 linker, Formula IV)

15

Primers

BAF: CAG CGG AAC CGC TCA TTG CCA ATG G  
BAR: TCA CCC ACA CTG TGC CCA TCT ACG A  
BAFR: CAG GTC CCG GCC AGC CAG

20

1. C282Y (HFE gene, C282Y mutation)

**[0070]**

25

Probe

C282YP: ATA TAC GTG CCA GGT GGA

Primers

30

C282YF: CTG GAT AAC TTG GCT GTA C  
C282YR: TCA GTC ACA TAC CCC AGA T

2. H63D (HFE gene, H63F mutation)

35

**[0071]**

Probe

40

H63DP: ATA TAC GTG CCA GGT GGA

Primers

45

H63DF: CTT GGT CTT TCC TTG TTT GAA G  
H63DR: ACA TCT GGC TTG AAA TTC TAC T

CFTR (cystic fibrosis transmembrane conductance regulator)

**[0072]**

50

Primers

CFT01: AGG CCT AGT TGT CTT ACA GTC CT  
CFT03: TGC CCC CTA ATT TGT TAC TTC

55

G6PC (glucose-6-phosphatase)

**[0073]**

Probe

GSDPR: TGT GGA TGT GGC TGA AAG TTT CTG AAC

5 Primers

GSDw: CCG ATG GCG AAG CTG AAC

GSDcom: TGC TTT CTT CCA CTC AGG CA

10 6. ACADM (medium chain acyl-CoA dehydrogenase)

[0074]

Probe

15

MC11PR: CTA GAA TGA GTT ACC AGA GAG CAG CTT GG

Primers

20 MC11w: GCT GGC TGA AAT GGC AAT GA

MC11com: CTG CAC AGC ATC AGT AGC TAA CTG A

7. Hairpin oligonucleotide

25 [0075]

reHP: CAG AAT ACA GCA GGT GCT CGC CCG GGC GAG CAC CTG TAT TCT G

8. Single strand oligonucleotide

30

[0076]

reBAF: CAG AAT ACA GCA GGT TCA CCC ACA CTG TGC CCA TCT ACG A

35 [0077] The oligonucleotide for use in examples 7 and 8 were C12 amino modified at the 5' end. The oligonucleotides for use in the other examples were unmodified.

#### Materials and Methods - Electrochemical Detection

40 [0078] The following electrodes and low volume cell were obtained from BAS, Congleton, Cheshire, UK:

Glassy carbon working electrode (catalogue number MF-2012) was used in examples 4 and 5. A Gold working electrode (catalogue number MF-2014) was used in examples 8 to 10.

45 Silver/silver chloride reference electrode (catalogue number MF-2079)

Platinum wire counter (auxiliary) electrode (catalogue number MW-4130).

50 Low volume cell (catalogue number MF-2040) comprising glass voltammetry vial and glass sample chamber, with replaceable vycor tip.

[0079] An AutoLab electrochemical workstation (either PGSTAT30 with frequency response analyzer or  $\mu$ AutoLab type II manufactured by Eco Chemie B.V) was obtained from Windsor scientific Limited.

55 EXAMPLE 1

[0080] This Example describes the cyclic voltammetry method used in Examples 3 to 5 and 8 to 10 below.

[0081] The low volume cell of Fig. 1 was filled with approximately 10ml ammonium acetate solution (100mM).

**[0082]** A 200  $\mu$ l aliquot of the sample for analysis was placed in the glass sample chamber 4 which was then placed in the low volume cell along with the reference 7 and counter electrodes 6. The electrodes were connected to an Autolab electrochemical workstation and differential pulse voltammetry carried out using the parameters described below. Prior to analysis the working electrode was polished (using BAS polishing kit catalogue number MF-2060) followed by conditioning. Electrode conditioning consisted of cyclic voltammetry, sweeping between +/- 1 volt in the appropriate background buffer.

Parameters for differential pulse voltammetry

**[0083]**

Table 1: Parameters used in Examples 4 and 5

Parameter:	Cathodic Sweep	Anodic Sweep
Conditioning potential (V)	0	0
Conditioning duration (s)	0	0
Deposition potential (V)	0.8	-0.1
Deposition duration (s)	5	5
Equilibration time (s)	0	0
Modulation time (s)	0.02	0.02
Interval time (s)	0.1	0.1
Initial potential (V)	0.75	-0.1
End potential (V)	0.1	0.7
Step potential (V)	0.005	0.005
Modulation amplitude (V)	0.1	0.1

Table 2: Parameters used in Example 8

Parameter:	Cathodic Sweep	Anodic Sweep
Conditioning potential (V)	0	0
Conditioning duration (s)	0	0
Deposition potential (V)	0	0
Deposition duration (s)	0	5
Equilibration time (s)	0	0
Modulation time (s)	0.04	0.04
Interval time (s)	0.1	0.1
Initial potential (V)	-0.1	0.3
End potential (V)	0.3	-0.1
Step potential (V)	0.0003	0.0003
Modulation amplitude (V)	0.05	0.05

Table 3: Parameters used in Examples 9 and 10

Parameter:	Anodic sweep
Conditioning potential (V)	0
Conditioning duration (s)	10

(continued)

Parameter:	Anodic sweep
Deposition potential (V)	0
Deposition duration (s)	0
Equilibration time (s)	0
Modulation time (s)	0.04
Interval time (s)	0.1
Initial potential (V)	-0.1
End potential (V)	0.7
Step potential (V)	0.003
Modulation amplitude (V)	0.05

**EXAMPLE 2 - Synthesis of *N*-hydroxysuccinimide ester of ferrocenecarboxylic acid**

**[0084]** Ferrocenecarboxylic acid (303mg, 1.32mmol) and *N*-hydroxysuccinimide (170mg, 1.47mmol) were dissolved in dioxane (15ml) and added with stirring to a solution of dicyclohexylcarbodiimide (305mg, 1.48mmol) in dioxane (3ml). The mixture was stirred at room temperature for 24 hours during which time a precipitate was formed. The precipitate was removed by filtration, solvent was removed from the filtrate *in vacuo* and the resulting solid purified by silica gel column chromatography, eluting with 8:2 petrol:ethyl acetate. Yield 320mg, 74%.

**EXAMPLE 3 - Synthesis of ferrocenyl oligonucleotides**

**[0085]** Lyophilised amino-modified oligonucleotide was rehydrated in the correct volume of  $K_2CO_3/KHCO_3$  buffer (500mM, pH 9.0) to give an oligonucleotide concentration of  $0.5nmol\mu l^{-1}$ . Amino-modified oligonucleotide ( $40\mu l$ ,  $0.5nmol\mu l^{-1}$ ) was added slowly with vortexing to a solution of the *N*-hydroxysuccinimide ester of ferrocenecarboxylic acid in DMF ( $40\mu l$ , 375mM). The solution was shaken at room temperature overnight. It was then diluted with ammonium acetate ( $920\mu l$ , 100mM, pH 7.0) and purified using two NAP 10 columns, eluting firstly with ammonium acetate (100mM, pH 7.0), and then with autoclaved deionised water. Ferrocenylated oligonucleotides were partially purified by NAP 10 column to remove salt and low molecular weight ferrocene species to give a mixture of ferrocene labelled and unlabelled oligonucleotides. No further purification was carried out before use. Amino-modified oligonucleotides possessing four different linker structures: C7, C6, C12 and T(C9), varying in structure and point of attachment, were used in labeling reactions. C6, C12 and T(C9) linkers were attached at the 5' end of the oligonucleotide, via the terminal phosphate ester or the base. The C7 linker was attached via the terminal phosphate ester at the 3' end of the oligonucleotide. The label structures are given in Formulae I to IV. Oligonucleotide concentration of the eluent was determined by measuring its absorbance at 260nm. Presence of the ferrocene label was confirmed by voltammetric analysis.

**EXAMPLE 4****S1 Nuclease digestion**

**[0086]** Oligonucleotide digestion reactions ( $100\mu l$ ) contained oligonucleotide ( $3.5-9\mu M$ , concentrations detailed below), ammonium acetate (250mM, pH 6.5), zinc acetate (4.5mM) and S1 Nuclease ( $0.4U\mu l^{-1}$ ). Reactions were incubated at  $37^\circ C$  for 1 hour. Complete digestion of the oligonucleotide was confirmed by polyacrylamide gel analysis of a  $10\mu l$  aliquot of the crude reaction mix. Multiple reactions were pooled prior to voltammetric analysis, to give a final volume of  $200\mu l$ . By way of comparison, "no-enzyme" reactions were performed as described above, omitting S1 Nuclease from the reaction mixture. Heated enzyme controls were performed as described above, using S1 Nuclease that had previously been thermally denatured by heating at  $95^\circ C$  for 15 minutes.

**[0087]** In the following, the reactants and conditions are as described above, and the voltammetry conditions are as given in Table 1 except where otherwise stated.

**Example 4(a):****[0088]**

Oligonucleotide: BAPR oligonucleotide labelled at 3' end by ferrocene with a 7-carbon spacer moiety (Formula I).  
 Concentration of oligonucleotide: 7.0 $\mu$ M  
 Voltammetry conditions: As in Table 1 except that the interval time was 0.09s and the modulation time 0.5s.

5 [0089] The results are shown in Fig. 2a (cathodic sweep of "no-enzyme" control), Fig. 2b (cathodic sweep of solution including S1 nuclease), Fig. 2c (anodic sweep of "no-enzyme" control) and 2d (anodic sweep of solution including S1 nuclease). The measured peak values, peak positions and % peak enhancement for the solution including S1 nuclease (that is, with digested oligonucleotide) as compared the "no-enzyme" control are given in Table 2.

10 Example 4(b):

[0090]

15 Oligonucleotide: BAPR oligonucleotide labelled at 5' end by ferrocene with a 6-carbon spacer moiety (Formula II).  
 Concentration of oligonucleotide: 7.0 $\mu$ M  
 Voltammetry conditions: As in Table 1 except that the interval time was 0.09s and the modulation time 0.5s.

20 [0091] The results are shown in Fig. 3a (cathodic sweep of "no-enzyme" control), Fig. 3b (cathodic sweep of solution including S1 nuclease), Fig. 3c (anodic sweep of "no-enzyme" control) and 3d (anodic sweep of solution including S1 nuclease). The measured peak values, peak positions and % peak enhancement for the solution including S1 nuclease (that is, with digested oligonucleotide) as compared the "no-enzyme" control are given in Table 2.

Example 4(c):

25 [0092]

Oligonucleotide: T1BAPR oligonucleotide labelled at 3' end base by ferrocene with a 9-carbon spacer moiety (Formula IV).  
 Concentration of oligonucleotide: 8.8 $\mu$ M.  
 30 Voltammetry conditions: As in Table 1

[0093] The results are shown in Fig. 4a (cathodic sweep of "no-enzyme" control), Fig. 4b (cathodic sweep of solution including S1 nuclease), Fig. 4c (anodic sweep of "no-enzyme" control) and 4d (anodic sweep of solution including S1 nuclease). The measured peak values, peak positions and % peak enhancement for the solution including S1 nuclease (that is, with digested oligonucleotide) as compared the "no-enzyme" control are given in Table 2.

Example 4(d):

40 [0094]

Oligonucleotide: BAPR oligonucleotide labelled at 5' end by ferrocene with a 12-carbon spacer moiety (Formula III).  
 Concentration of oligonucleotide: 7.0 $\mu$ M.  
 Voltammetry conditions: As in Table 1 except that the interval time was 0.09s and the modulation time 0.5s

45 [0095] The results are shown in Fig. 5a (cathodic sweep of "no-enzyme" control), Fig. 5b (cathodic sweep of solution including S1 nuclease), Fig. 5c (anodic sweep of "no-enzyme" control) and 5d (anodic sweep of solution including S1 nuclease). The measured peak values, peak positions and % peak enhancement for the solution including S1 nuclease (that is, with digested oligonucleotide) as compared the "no-enzyme" control are given in Table 2.

50 Example 4(e):

[0096]

55 Oligonucleotide: GSDPR oligonucleotide labelled at 5' end by ferrocene with a 12-carbon spacer moiety (Formula III).  
 Concentration of oligonucleotide: 3.5 $\mu$ M.  
 Voltammetry conditions: As in Table 1.

[0097] The results are shown in Fig. 6a (cathodic sweep of "no-enzyme" control), Fig. 6b (cathodic sweep of solution



including S 1 nuclease), Fig. 6c (anodic sweep of "no-enzyme" control) and 6d (anodic sweep of solution including S 1 nuclease). The measured peak values, peak positions and % peak enhancement for the solution including S 1 nuclease (that is, with digested oligonucleotide) as compared the "no-enzyme" control are given in Table 2.

5 Example 4(f):

**[0098]**

10 Oligonucleotide: MC11PR oligonucleotide labelled at 5' end by ferrocene with a 12-carbon spacer moiety (Formula III).  
Concentration of oligonucleotide: 3.5 $\mu$ M.  
Voltammetry conditions: As in Table 1.

15 **[0099]** The results are shown in Fig. 7a (cathodic sweep of "no-enzyme" control), Fig. 7b (cathodic sweep of solution including S1 nuclease), Fig. 7c (anodic sweep of "no-enzyme" control) and 7d (anodic sweep of solution including S1 nuclease). The measured peak values, peak positions and % peak enhancement for the solution including S 1 nuclease (that is, with digested oligonucleotide) as compared the "no-enzyme" control are given in Table 2.

20 Example 4(g) (comparison):

**[0100]**

Oligonucleotide: BAFR, unlabelled.  
Concentration of oligonucleotide: 8.8 $\mu$ M.  
25 Voltammetry conditions: As in Table 1

**[0101]** The results are shown in Fig. 8a (cathodic sweep) and Fig. 8b (anodic sweep). No peak was observed in either sweep.

30 Example 4(h)(Comparison):

**[0102]**

35 Oligonucleotide: T1BAPR oligonucleotide labelled at 5' end base by ferrocene with a 9-carbon spacer moiety (Formula IV).  
Concentration of oligonucleotide: 8.8 $\mu$ M.  
Voltammetry conditions: As in Table 1.

40 **[0103]** The results are shown in Fig. 9a (anodic sweep of "no-enzyme" control) and Fig. 9b (anodic sweep of heated enzyme control including S1 nuclease). In Fig. 9a, a peak height of 60.6 $\mu$ A (peak position 424mV) was recorded, whilst in Fig. 9b, a peak height of 39.9 $\mu$ A (peak position 409mV) was recorded.

**[0104]** Ferrocene related peaks were observed at 300-500mV. No peaks were observed in this range when non-ferrocenylated oligonucleotides were analysed (Figs. 8a and 8b). Comparison of digested ferrocene labelled oligonucleotides and no-enzyme controls showed that an increase in peak height was obtained on digestion of the oligonucleotide (Table 4).  
45

**[0105]** In order to confirm that the observed changes were not due to the presence of enzyme, or components of the enzyme storage buffer, digestion experiments were also performed using heat-denatured enzyme (Example 4(h)). No significant changes to the ferrocene signal were observed when comparing heat denatured enzyme and no enzyme controls.

50 **[0106]** Digestion experiments of two additional oligonucleotide sequences with the C12 ferrocene-oligonucleotide linker were performed; Ferrocene-C12-MC11PR and Ferrocene-C12-GSDPR (Figures 6 and 10). An increase in peak height of the ferrocene related signal of digested oligonucleotide was observed for each sequence.

55

Table 4: Positions and heights for ferrocene related peaks on anodic and cathodic differential pulse voltammograms

Cathodic Sweeps					
	Undigested		Digested		
5	Oligo	Peak position	Peak Height	Peak Position	Peak Height
					% increase in peak height upon digestion
	BAPR C7	419	-4.65	424	-10.16
10	BAPR C6	424	-3.24	444	-8.87
	T1BAPR C9	518	-94.1	533	-456.5
	BAPR C12	-	-	500	-4.71
15	GSDPR C12	533	-30.5	554	-65.43
	MC11PR C12	553	-21.9	564	-49
					218
					274
					485
					215
					224
Anodic Sweeps					
	Undigested		Digested		
20	Oligo	Peak position	Peak Height	Peak Position	Peak Height
					% increase in peak height upon digestion
	BAPR C7	394	3.39	394	9.18
25	BAPR C6	399	1.63	419	10.3
	T1BAPR C9	434	82.8	444	818
	BAPR C12	-	-	494	6.7
30	GSDPR C12	434	62.9	394	359
	MC11PR C12	429	60.1	394	196
					266
					632
					988
					571
					326

**EXAMPLE 5 - PCR**

35 **[0107]** PCR amplification was performed from human genomic DNA (40ng per 100µl reaction), or gel purified PCR amplicons. PCR amplicons used for subsequent amplifications were purified by agarose gel with Nucleospin Extract kits (Macherey-Nagel) following the protocol supplied. All ferrocenyl oligonucleotide probes were 3' phosphorylated.

**[0108]** Primers, template and probe used for individual reactions are detailed above.

40 **[0109]** 100µl reactions contained Tris HCl (15mM, pH 8.0), potassium chloride (50mM), magnesium chloride (3.5mM), dATP, TTP, dCTP, dGTP (200µM each), forward primer (1.0µM), reverse primer (1.0µM), ferrocenyl oligonucleotide probe (0.9µM), AmpliTaq Gold (0.04 Uµl<sup>-1</sup>). Samples were incubated at 95°C for 10 minutes (initial denaturation and enzyme activation) followed by 40 cycles of denaturation at 95°C for 15s, and primer annealing and extension at 60°C for 1 min.

45 **[0110]** Fifteen 100µl reactions were prepared and pooled. The crude reaction mixture was then concentrated to 200µl total volume prior to voltammetric analysis.

**[0111]** In the following, the reactants and conditions are as described above and the voltammetry conditions are as given in Table 1 unless otherwise stated.

50 **Example 5(a):**

**[0112]**

Oligonucleotide: BAPR oligonucleotide labelled at 5' end with a 12-carbon spacer moiety (Formula III).

55 Positive reaction: (β actin) template: β actin PCR amplicon; primers: BAF, BAR.

Negative reaction: (cystic fibrosis transmembrane conductance regulator) template: cystic fibrosis PCR amplicon; primers: CFT 01, CFT 03.

Voltammetry conditions: As in Table 1.

[0113] The results were as follows:

Figure 10a negative reaction, cathodic sweep, no peak observed

Figure 10b positive reaction, cathodic sweep, peak position: 493mV, peak height: - 19.4nA.

Figure 10c negative reaction, anodic sweep, no peak observed.

Figure 10d positive reaction, anodic sweep, peak position: 373mV, peak height: 27.3nA.

Example 5(b):

[0114]

Oligonucleotide: MC11PR oligonucleotide labelled at 5' end with a 12-carbon spacer moiety (Formula III).  
Positive reaction: (Medium chain acyl-CoA dehydrogenase) template: MCAD PCR amplicon or genomic template;  
primers: MC11w, MC11com;  
Negative reaction: (glucose-6-phosphatase) template: Glucose-6-Phosphatase PCR amplicon; primers: GSDw,  
GSDcom;

Figure 11a negative reaction, anodic sweep, peak position: 429mV, peak height: 1.84nA.

Figure 11b positive reaction (PCR amplicon template), anodic sweep, peak position: 388mV, peak height: 7.62nA.

Figure 11c positive reaction (genomic template), anodic sweep, peak position: 409mV, peak height: 8.11nA.

Example 5(c)

[0115]

Oligonucleotide: T1BAPR oligonucleotide labelled at 5' end with a 9-carbon spacer moiety.  
Positive reaction: ( $\beta$  actin) template: human genomic DNA; primers:  
BAF, BAR.  
Negative reaction: (glucose-6-phosphatase) template: human genomic DNA; primers: GSDw, GSDcom.

Voltammetry conditions: as in Table 1.

[0116] The results were as follows:

Figure 12a: negative reaction, anodic sweep.

Figure 12b: positive reaction, anodic sweep, peak position: 429mV, peak height: 36nA.

Figure 12c: negative reaction cathodic sweep.

Figure 12d: positive reaction cathodic sweep, peak position: 498mV, peak height: 14nA.

Example 5(d)

[0117]

Oligonucleotide GSDPR labelled at 5' end with a 12 carbon spacer moiety.  
Positive reaction: (glucose-6-phosphatase) template: human genomic DNA; primers: GSDw, GSDcom.  
Negative reaction: ( $\beta$  actin) template: human genomic DNA; primers: BAF, BAR.

Figure 13a: negative reaction, anodic sweep.

Figure 13b: positive reaction, anodic sweep, peak, position: 439mV, peak height: 23nA.

Figure 13c: negative reaction cathodic sweep.


Figure 13d: positive reaction cathodic sweep.

[0118] In this example, to demonstrate the sequence specific detection of PCR products with ferrocenylated oligonucleotide probes, probe and primer sequences from previously optimized fluorogenic 5' nuclease assays were used. PCR

**[0120]** Voltammetric analysis was performed on the crude PCR mixes (Figures 10 and 11). In each case a ferrocene related signal is observed for positive reactions (containing digested probe). No signal is observed for negative reactions (containing undigested probe).

**[0121]** Ferrocene carbonyl azide was prepared from ferrocenecarboxylic acid by reaction with oxalyl chloride and sodium azide.


**[0122]**



**[0123]** To a purged round-bottom flask was charged ferrocene carbonyl azide (300mg, 1.18 mmol, 1.00 equiv.), 4-aminobenzoic acid (244mg, 1.78 mmol, 1.50 equiv.) and 1,4-dioxane (40 ml) under nitrogen. The reaction mixture was stirred under nitrogen in a 100°C bath for 2 hr 50 min and then allowed to cool to room temperature. 2M HCl (100 ml) was charged to the reaction mixture and the product was extracted into ethyl acetate (150 ml). This phase was washed with 2M HCl (100 ml), dried with sodium sulphate and concentrated *in vacuo* to afford the product. Further drying in a vacuum oven yielded as orange crystals (413mg 96%). <sup>1</sup>H-NMR δ (300MHz, d<sub>6</sub>-DMSO) 3.96 (2H, b, Hc), 4.14 (5H, s, Ha), 4.53 (2H, b, Hb), 7.54 (2H, m, Hf), 7.85 (2H, m, Hg), 7.98 (1H, s, Hd), 8.87 (1H, s, He) 12.57 (1H, s, Hh) <sup>13</sup>C-NMR δ (75.5MHz, d<sub>6</sub>-DMSO) 61.0 64.1 66.7 68.1 (Ca,d), 117.2 (Cg), 123.5 (Cj), 130.9 (Ch), 144.6 (Cf), 152.8 (Ce).

**[0124]** Dicyclohexylcarbodiimide (DCC) (194 mg, 0.939 mmol, 1.14 equiv.) was dissolved in anhydrous 1,4-Dioxane (2 ml) and charged to a purged round-bottom flask, under nitrogen. *N*-hydroxysuccinimide (108 mg, 0.939 mmol, 1.14 equiv.) was charged. 4-(3'-Ferrocenylureido)-1-benzoic acid (300 mg, 0.823 mmol 1.0 equiv.) was dissolved in anhydrous 1,4-Dioxane (13 ml) and charged dropwise to the flask. The solution was stirred at room temperature for 23 hr. A small amount of light brown solid was removed from the red/orange reaction mixture by Buchner filtration. Water (100 ml) and ethyl acetate (50 ml) were charged to the reaction mixture. The ethyl acetate phase was separated and the aqueous was extracted with ethyl acetate (100 ml). The ethyl acetate phases were combined, dried with sodium sulphate and concentrated *in vacuo* to afford the crude product as an orange oil, which was purified using silica flash chromatography with a gradient system from ethyl acetate 60/ petroleum ether (bp 40-60 °C) 40 to ethyl acetate. Drying in a vacuum oven yielded *N*-hydroxysuccinimide ester of 4-(3'-ferrocenylureido)-1-benzoic acid as fine orange crystals (237 mg, 66%). R<sub>f</sub> (5:1 ethyl acetate / petroleum ether (bp 40-60 °C)) = 0.41 <sup>1</sup>H-NMR δ (300MHz, d<sub>6</sub>-DMSO) 2.88 (4H, s, Hh), 3.98 (2H, t, J = 1.8 Hz, Hc), 4.16 (5H, s, Ha), 4.55 (2H, t, J = 1.8 Hz, Hb), 7.68 (2H, m, Hf), 8.00 (2H, m, Hg), 8.11 (1H, s, Hd), 9.16 (1H, s, He). <sup>13</sup>C-NMR δ (75.5MHz, d<sub>6</sub>-DMSO) 25.9 (Ci), 61.1 64.2 (Cb and Cc), 69.1 (Ca), 117.7 (Cg), 131.9 (Ch), 170.9 (Ck). MS (FAB+ m/z) 462.07 [M+11].

**[0125]**



**[0126]** To a purged round-bottom flask was charged ferrocene carbonyl azide (800mg, 3.14 mmol, 2.5 equiv.), 3,5-diaminobenzoic acid (194mg, 1.25 mmol, 1.00 equiv.) and 1,4-dioxane (60 ml) under nitrogen. The reaction mixture was stirred under nitrogen in a 100°C bath for 1 hr and then allowed to cool to room temperature. Water (300 ml) and ethyl acetate (150 ml) were charged to the reaction mixture. To improve separation the aqueous phase was acidified with HCl. The ethyl acetate phase was washed with water (100 ml) and on standing solid began to precipitate. The solution was concentrated *in vacuo* to afford the crude product as an orange oil, which was dried with a toluene azeotrope (100 ml), to yield a light orange solid. The product was purified using silica flash chromatography using gradient system from DCM 90/MeOH 10 to DCM 50/MeOH 50. Drying in a vacuum oven yielded (19) as orange crystals (205 mg, 27%). <sup>1</sup>H-NMR  $\delta$  (300MHz, d<sub>6</sub>-DMSO) 3.95 (4H, b, Hc), 4.14 (10H, s, Ha), 4.54 (4H, b, Hb), 7.69 (2H, s, Hf), 7.81 (1H, s, Hg), 8.08 (2H, s, Hd), 8.94 (2H, s, He). MS (FAB+ *m/z*) 607.07 [M+H].

#### EXAMPLE 7 - Synthesis of 4-(3'-ferrocenylureido)-1-benzoic acid oligonucleotides

**[0127]** Lyophilised amino-modified oligonucleotide was rehydrated in the correct volume of K<sub>2</sub>CO<sub>3</sub>/KHCO<sub>3</sub> buffer (500mM, pH 9.0) to give an oligonucleotide concentration of 0.5nmol $\mu$ l<sup>-1</sup>. Amino-modified oligonucleotide (40 $\mu$ l, 0.5nmol $\mu$ l<sup>-1</sup>) was added slowly with vortexing to a solution of the ferrocene activated ester in DMSO (40 $\mu$ l, 375mM). The solution was shaken at room temperature overnight, it was then diluted with ammonium acetate (920 $\mu$ l, 100mM, pH 7.0) and purified using two NAP 10 columns (following the protocol supplied), eluting firstly with ammonium acetate (100mM, pH 7.0), and then with autoclaved deionised water. Oligonucleotide concentration of the eluent was determined by measuring its absorbance at 260nm. Presence of the ferrocene label was confirmed by voltammetric analysis.

#### EXAMPLE 8 - S1 Nuclease and PCR with 4-(3'-ferrocenylureido)-1-benzoic acid labelled substrates/probes

**[0128]** By use of 4-(3'-ferrocenylureido)-1-benzoic acid labelled substrates/probes and the voltammetry parameters as set out in table 2, Examples 4 and 5 were repeated with the concentrations of all reagents as described in those examples. The peak potential of the 4-(3'-ferrocenylureido)-1-benzoic acid nucleotides is lower than that of the ferrocene labelled nucleotides. That increases the sensitivity with which the electrochemical marker can be detected. In the Example 8 experiments it was, accordingly, not necessary to carry out the sample concentration step used in Example 4 and 5 and the method protocol was significantly simplified. The results for Example 8 (not shown) demonstrate that good sensitivity is observed without the sample concentration step.

#### EXAMPLE 9 - T7 exonuclease substrate specificity

**[0129]** 200 $\mu$ l of hairpin oligonucleotide and 200 $\mu$ l of single stranded oligonucleotide were added to separate reaction tubes at a concentration of 7 $\mu$ M in 1 x T7 reaction buffer. T7 enzyme was added to each tube (5 $\mu$ l, 2U $\mu$ l<sup>-1</sup>) and the mixtures were incubated for 1 hour at 25 °C. Both oligos were previously labelled with Ferrocene via a C12 linker.

**[0130]** The results were as follows:

Fig. 16a: Line A - digestion of hairpin oligonucleotide duplex.

Fig. 16a: Line B - hairpin oligonucleotide duplex no enzyme control.

Fig. 16b: Line A - digestion of single stranded oligonucleotide.

Fig. 16b: Line B - single stranded oligonucleotide no enzyme control.

#### EXAMPLE 10 - PCR amplification with T7 exonuclease digestion

Example 10 (a)

**[0131]** PCR amplification with 5' ferrocenylated primer and T7 exonuclease digestion PCR amplification was performed

from human genomic DNA (40ng per 100 $\mu$ l reaction). Primers, template and probe used for individual reactions are detailed in the results section. 100 $\mu$ l reactions contained Tris HCl (15mM, pH 8.0), potassium chloride (50mM), magnesium chloride (3.5mM), dATP, TTP, dCTP, dGTP (200 $\mu$ M each), 5' ferrocenylated forward primer (0.5 $\mu$ M), reverse primer (0.5 $\mu$ M), Amplitaq Gold DNA Polymerase (0.1 U $\mu$ l<sup>-1</sup>), BSA (0.1mg $\mu$ l<sup>-1</sup>). Samples were incubated at 95°C for 10 minutes (initial denaturation and enzyme activation) followed by 40 cycles of denaturation at 95°C for 15s, and primer annealing and extension at 60°C for 1 min. Samples were immediately cooled to 25°C and incubated at 25°C for 5 minutes. T7 exonuclease (5 $\mu$ l, 2U $\mu$ l<sup>-1</sup>) was added to the crude PCR mix and samples incubated for a further 20 minutes. Two 100 $\mu$ l reactions were prepared and pooled prior to voltammetric analysis.

[0132] The results were as follows:

Forward primer: MW11w ferrocenylated via a C12 linker

Reverse primer: MC11com

Fig. 17a: Line A - MCAD PCR amplification positive PCR

Fig. 17a: Line B - MCAD PCR no Taq negative control

Fig. 17b: Lines A and B - as Fig 17a but with baseline corrected data

Example 10(b)

[0133]

PCR amplification with unmodified primers, end point probe annealing and T7 exonuclease digestion

PCR amplifications were performed as described above. On completion of the PCR, samples were heated to 95°C for 2 minutes, during this time ferrocenylated oligonucleotide probe was added (0.5 $\mu$ M final concentration). Samples were cooled to 25°C and incubated at 25°C for 5 minutes. T7 exonuclease (5 $\mu$ l, 2U $\mu$ l<sup>-1</sup>) was added to the crude PCR mix and samples incubated for a further 20 minutes.

Two 100 $\mu$ l reactions were prepared and pooled prior to voltammetric analysis.

[0134] The results were as follows:

Beta actin PCR amplification Line A shows positive PCR target amplification reaction and line B shows non-target amplification control throughout

Probe: BAPR ferrocenylated via a C12 linker

Forward target amplification primer: BAF

Reverse target amplification primer: BAR

Forward non-target amplification primer: GSDF

Reverse non-target amplification primer: GSDR

Fig. 18a: normal data, anodic sweep

Fig-18b: baseline corrected data, anodic sweep

HFE gene PCR amplification Line A shows positive PCR target amplification reaction and line B shows non-target amplification control throughout

Probe: H63DP ferrocenylated via a C12 linker

Forward target amplification primer: H63DF

Reverse target amplification primer: H63DR

Forward non-target amplification primer: C282YF

Reverse non-target amplification primer: C282YR

Fig. 19a: normal data, anodic sweep

Fig. 19b: baseline corrected data, anodic sweep

HFE gene PCR C282Y mutation amplification Line A shows positive PCR target amplification reaction and line B shows non-target amplification control throughout

Probe: C282YP ferrocenylated via a C12 linker

Forward target amplification primer: C282YF

Reverse target amplification primer: C282YR

Forward non-target amplification primer: H63DF

Reverse non-target amplification primer: H63DR

Fig. 20a: normal data, anodic sweep

Fig. 20b: baseline corrected data, anodic sweep

Example 10(c)**[0135]**

5 PCR amplification with unmodified primers, end point probe annealing and T7 exonuclease digestion: Stoffel Fragment

10 PCR, probe annealing and T7 exonuclease digestion was performed as described in the above section, substituting Amplitaq Gold DNA Polymerase and supplied buffer with Amplitaq DNA Polymerase Stoffel Fragment and supplied buffer.

**[0136]** The results were as follows:

15 HFE gene PCR amplification Line A shows positive PCR target amplification reaction and line B shows non-target amplification control throughout

Probe: C282YP ferrocenylated via a C12 linker

Forward target amplification primer: C282YF

Reverse target amplification primer: C282YR

Forward non-target amplification primer: H63DF

20 Reverse non-target amplification primer: H63DR

Fig. 21a: normal data, anodic sweep

Fig. 21b: baseline corrected data, anodic sweep

Example 10(d)

25

**[0137]**

30 PCR amplification with unmodified primers, end point probe annealing and T7 exonuclease digestion: No T7 exonuclease control

PCR and probe annealing was performed as described in example 9c, using Amplitaq Gold DNA polymerase. No T7 exonuclease was added to the PCR mix.

**[0138]** The results were as follows:

35

HFE gene PCR amplification Line A shows positive PCR target amplification reaction and line B shows non-target amplification control throughout

Probe: C282YP ferrocenylated via a C 12 linker

Forward target amplification primer: C282YF

40 Reverse target amplification primer: C282YR

Forward non-target amplification primer: H63DF

Reverse non-target amplification primer: H63DR

Fig. 22a: normal data, anodic sweep

45 Fig. 22b: baseline corrected data, anodic sweep

EXAMPLE 11 - Differential pulse voltammogram analysis of ferrocene carboxylic acid and 4-(3'-ferrocenylureido)-1-benzoic acid

50 **[0139]** Solutions of ferrocene carboxylic acid and 4-(3'-ferrocenylureido)-1-benzoic acid were prepared at 10 $\mu$ M and 1 $\mu$ M concentration in 100mM aqueous sodium chloride with 10% DMSO. 200 $\mu$ l sample volumes were used for differential pulse analysis in an apparatus as described in Example 1 with a gold working electrode. The differential pulse conditions were as in Table 3. The voltammograms are shown in Figure 23 in which Fig 23(a) and (b) show the voltammograms for ferrocene carboxylic acid at 10 $\mu$ M and 1 $\mu$ M respectively, and

55 Figs 23 (c) and (d) show the voltammograms for 4-(3'-ferrocenylureido)-1-benzoic acid at 10 $\mu$ M and 1 $\mu$ M respectively.

EXAMPLE 12 - Differential pulse voltammogram analysis of S1 Nuclease digestion of a mixture of ferrocenylated oligonucleotides.

**[0140]** Three oligonucleotide digestion reactions were carried out as detailed above in Example 4. In reaction (a) the substrates were BAPR oligonucleotide labelled at the 5' end by ferrocene with a 12 carbon spacer moiety (2.5 $\mu$ M) and MC11w oligonucleotide labelled at the 5' end by 4-(3-ferrocenylureido)-1-benzoic acid with a 12 carbon spacer moiety (1.5 $\mu$ M). In reaction (b), the substrate was BAPR oligonucleotide labelled at the 5' end by ferrocene with a 12 carbon spacer moiety only (2.5 $\mu$ M). In reaction (c), the substrate was MC11w oligonucleotide labelled at the 5' end by 4-(3-ferrocenylureido)-1-benzoic acid with a 12 carbon spacer moiety only (1.5 $\mu$ M).

**[0141]** After completion of each digestion reaction, the reaction mixtures were analysed by differential pulse voltammetry under the conditions detailed in table 3, except that the end potential was 0.5V. A gold working electrode was used. The voltammograms are presented in Figures 24 (a), (b) and (c) respectively. Data is presented with baseline correction. As is seen in the figures, the 4-(3-ferrocenylureido)-1-benzoic acid label has a peak in the differential pulse voltammogram at around 130mV whilst the ferrocene label has a peak at around 370mV. The peaks are sufficiently far apart to be resolvable in a mixture as seen in Figure 24(a). The resolvability of the two peaks makes the two labels suitable for use in a multiplex experiment in which two different target sequences are simultaneously probed in the same reaction mixture.

**Claims**

1. A method of probing for a nucleic acid comprising: contacting a nucleic acid solution with an oligonucleotide probe labelled with an electrochemically active marker, providing conditions at which the probe is able to at least partially hybridise with any complementary target sequence which may be present in the nucleic acid solution, selectively degrading either hybridised, partially hybridised or unhybridised nucleic acid probe, and electrochemically determining information relating to the electrochemically active marker.
2. A method as claimed in claim 1, wherein the information relating to the marker is used to derive information concerning the presence or absence of at least one nucleic acid species.
3. A method as claimed in claim 1 or claim 2, wherein the electrochemical technique is used to quantify relative proportions of degraded and non-degraded probe.
4. A method as claimed in any one of claims 1 to 3, wherein nucleic acid probe that has failed to successfully hybridise is digested by an enzyme that has been chosen to selectively digest single stranded unhybridised nucleic acid.
5. A method as claimed in any one of claims 1 to 3, wherein nucleic acid probe that has successfully hybridised is digested by an enzyme that has been chosen to selectively digest at least one strand of double stranded hybridised nucleic acid.
6. A method as claimed in claim 5, wherein the enzyme is a 5' nuclease.
7. A method as claimed in claim 6, wherein the 5' nuclease is also a DNA polymerase.
8. A method as claimed in claim 7, wherein the 5' nuclease/DNA polymerase is a thermostable enzyme.
9. A method as claimed in claim 8, wherein the thermostable enzyme is Taq polymerase.
10. A method as claimed in claim 8 or claim 9, wherein the reaction mixture also comprises a pair of primers suitable for extension by the DNA polymerase.
11. A method as claimed in claim 10, wherein reaction conditions and temperature cycling are suitable for a polymerase chain reaction (PCR) to take place concomitant to the 5' nuclease digestion of probe.
12. A method as claimed in any one of claims 1 to 3, in which a first oligonucleotide probe labelled with an electrochemically active marker is prevented from complete hybridisation by competition from a second oligonucleotide, and the resultant partially hybridised oligonucleotide labelled with an electrochemically active marker is cleaved by an enzyme that specifically recognises the configuration of the two oligonucleotides hybridised onto the target nucleic acid, said



cleavage effectively shortening the oligonucleotide portion to which the electrochemically active marker is attached.

13. A method as claimed in any one of claims 1 to 3, in which a first oligonucleotide probe is prevented from complete hybridisation by competition from a second oligonucleotide, and the resultant partially hybridised first oligonucleotide probe is cleaved by an enzyme that specifically recognises the configuration of the two oligonucleotides hybridised onto the target nucleic acid, the cleavage product being recognised by a recognition cassette which comprises at least one oligonucleotide and is able to hybridise to the first cleavage product to produce an oligonucleotide configuration recognisable by an enzyme that cleaves a region of the recognition cassette that is labelled with an electrochemically active marker.
14. A method as claimed in any one of the preceding claims for the detection of nucleic acid polymorphisms.
15. A method as claimed in any one of claims 1 to 13 for the quantification of nucleic acid species.
16. A method of detecting a specific protein or group of proteins, comprising: contacting a protein solution with an oligonucleotide probe labelled with an electrochemically active marker, providing conditions at which the probe is able to bind to any specific protein or group of proteins that may be present in the solution, selectively degrading unhybridised nucleic acid probe, and electrochemically determining information relating to the electrochemically active marker in order to provide information about the presence, absence or relative or absolute amounts of the specific target protein or group of target proteins present in said solution.
17. A method as claimed in claim 16, wherein the unhybridised nucleic acid is degraded by an enzyme.
18. A method as claimed in claim 16 or claim 17 for the detection of protein polymorphisms.
19. A method as claimed in any one of claims 16 to 18 for the quantification of protein expression.
20. A method as claimed in any one of the preceding claims, wherein the electrochemical method is voltammetry.
21. A method as claimed in any one of claims 1 to 19, wherein the electrochemical technique is an amperometric technique.
22. A method as claimed in claim 20, wherein the method used is differential pulse voltammetry.
23. Use of a method as claimed in any one of the preceding claims in the detection of a genetic disease or a genetic disease carrier status or a genetic predisposition to disease.
24. Use of a method as claimed in any one of claims 1 to 22 to detect or identify a pathogen in a sample.
25. Use of a method as claimed in any one of claims 1 to 22 to predict a response of an organism to a therapeutic or toxic agent.
26. Use of a nucleic acid probe molecule comprising an oligonucleotide of specific sequence covalently linked to one or more electrochemically active marker moieties in a method as claimed in any one of claims 1 to 22.
27. Use as claimed in claim 26, wherein an electrochemically active marker is attached to the 3' end of the oligonucleotide probe.
28. Use as claimed in any one of claims 26 to 27, wherein an electrochemically active marker is attached to the 5' end of the oligonucleotide probe.
29. Use as claimed in any one of claims 26 to 28, wherein multiple electrochemically active markers are attached along the length of the oligonucleotide probe.
30. Use as claimed in any one of claims 26 to 29, wherein an electrochemically active marker is attached to substantially all of nucleotide residues of the oligonucleotide probe.
31. Use as claimed in any one of claims 26 to 29, wherein one of more electrochemically active marker moiety is as

according to formula I, II, III, IV, VII or VIII.

32. Use as claimed in any one of claims 26 to 29, wherein the oligonucleotide component is phosphorylated at both the 3' and 5' ends.
33. Apparatus arranged to carry out any one or more of method claims 1 to 22 comprising one or more sample receiving regions for receiving one or more samples, wherein the apparatus comprises a thermal cycler and the apparatus comprises apparatus for voltammetry.
34. A method as claimed in any one of claims 1 to 22, in which two or more oligonucleotide probes are used, each probe being labelled with a different electrochemically active marker.
35. A method as claimed in claim 34, in which the two or more electrochemically active markers have peaks in their voltammogram traces that are resolvable from each other.

# Patentansprüche

1. Verfahren zum Sondieren einer Nukleinsäure, bei welchem man:
- eine Nukleinsäurelösung mit einer Oligonukleotidsonde in Berührung bringt, die mit einem elektrochemisch aktiven Marker markiert ist, Bedingungen schafft, bei denen die Sonde in der Lage ist, wenigstens teilweise mit jeglicher komplementärer Target Sequenz zu hybridisieren, die in der Nukleinsäurelösung vorhanden sein kann, entweder hybridisierte, partiell hybridisierte oder nicht hybridisierte Nukleinsäuresonde selektiv abbaut, und elektrochemisch Informationen nachweist, die sich auf den elektrochemisch aktiven Marker beziehen.
2. Verfahren nach Anspruch 1, wobei die Informationen, die sich auf den Marker beziehen, eingesetzt werden, um Informationen betreffend die Gegenwart oder Abwesenheit wenigstens einer Nukleinsäurespezies abzuleiten.
3. Verfahren nach Anspruch 1 oder Anspruch 2, wobei die elektrochemische Technik eingesetzt wird, um die relativen Anteile von abgebauter und nicht abgebauter Sonde zu quantifizieren.
4. Verfahren nach einem der Ansprüche 1 bis 3, wobei Nukleinsäuresonde, welche nicht erfolgreich hybridisierte, mittels eines Enzyms abgebaut wird, das so ausgewählt wurde, dass einsträngige nicht hybridisierte Nukleinsäure selektiv abgebaut wird.
5. Verfahren nach einem der Ansprüche 1 bis 3, wobei Nukleinsäuresonde welche erfolgreich hybridisiert wurde, mittels eines Enzyms abgebaut wird, das so ausgewählt worden ist, dass es wenigstens einen Strang von doppelsträngiger hybridisierter Nukleinsäure selektiv abbaut.
6. Verfahren nach Anspruch 5, wobei das Enzym eine 5' Nuklease ist.
7. Verfahren nach Anspruch 6, wobei die 5' Nuklease auch eine DNA-Polymerase ist.
8. Verfahren nach Anspruch 7, wobei die 5' Nuklease/DNA-Polymerase ein thermostabiles Enzym ist.
9. Verfahren nach Anspruch 8, wobei das thermostabile Enzym Taq-Polymerase ist.
10. Verfahren nach Anspruch 8 oder Anspruch 9, wobei die Reaktionsmischung ebenfalls ein Paar von Primern aufweist, die zur Verlängerung mittels der DNA-Polymerase geeignet sind.
11. Verfahren nach Anspruch 10, wobei die Reaktionsbedingungen und Temperatur geeignet sind, dass eine Polymerasekettenreaktion (polymerase chain reaction - PCR) zugleich mit dem 5' Nukleaseabbau der Sonde stattfinden kann.
12. Verfahren nach einem der Ansprüche 1 bis 3, bei welchem eine erste Oligonukleotidsonde, die mit einem elektrochemisch aktiven Marker markiert ist, vor vollständige Hybridisierung durch Wettbewerb eines zweiten Oligonukleo-

tids geschützt ist, und das resultierende partiell hybridisierte Oligonukleotid, das mit einem elektrochemischen Marker markiert ist, mittels eines Enzyms gespalten wird, das spezifisch die Konfiguration der zwei Oligonukleotide erkennt, die auf die Zielnukleinsäure (Targetnukleinsäure) hybridisiert sind, wobei die Spaltung den Oligonukleotidabschnitt wirksam kürzt, an welchen der elektrochemisch aktive Marker gebunden ist.

- 5
13. Verfahren nach einem der Ansprüche 1 bis 3, bei welchem eine erste Oligonukleotidsonde vor vollständiger Hybridisierung, durch Wettbewerb eines zweiten Oligonukleotids geschützt wird, und die resultierende partielle hybridisierte erste Oligonukleotidsonde durch ein Enzym gespalten wird, das spezifisch die Konfiguration der zwei Oligonukleotide erkennt, die auf die Zielnukleinsäure (Targetnukleinsäure) hybridisiert sind, wobei das Spaltprodukt durch  
10 eine Erkennungskassette erkannt wird, welche wenigstens ein Oligonukleotid umfasst und in der Lage ist, an das erste Spaltprodukt zu hybridisieren, um eine Oligonukleotidkonfiguration herzustellen, die durch ein Enzym erkennbar ist, welches eine Region der Erkennungskassette spaltet, die mit einem elektrochemisch aktiven Marker markiert ist.
- 15 14. Verfahren nach einem der vorhergehenden Ansprüche zur Detektion von Nukleinsäurepolymorphismen.
15. Verfahren nach einem der Ansprüche 1 bis 13 zur Quantifizierung von Nukleinsäurespezies.
- 20 16. Verfahren zum Detekieren eines spezifischen Proteins oder Gruppe von Proteinen, bei welchem man:  
eine Proteinlösung mit einer Oligonukleotidsonde in Berührung bringt, die mit einem elektrochemisch aktiven Marker markiert ist,  
Bedingungen schafft, bei denen die Sonde in der Lage ist, an ein spezifisches Protein oder Gruppe von Proteinen zu binden, die in der Lösung vorhanden sein können,  
25 selektiv nicht hybridisierte Nukleinsäuresonde abbaut,  
und Information elektrochemisch nachweist, die sich auf den elektrochemisch aktiven Marker bezieht, um Informationen über die Anwesenheit, Abwesenheit oder relative oder absolute Menge des spezifischen Zielproteins (Targetproteins) oder Gruppe von Zielproteinen (Targetproteinen), die in der Lösung vorhanden sind, bereit zu stellen.  
30
17. Verfahren nach Anspruch 16, wobei die nicht hybridisierte Nukleinsäure mittels eines Enzyms abgebaut wird.
18. Verfahren nach Anspruch 16 oder Anspruch 17 zur Detektion von Proteinpotymorphismen.
- 35 19. Verfahren nach einem der Ansprüche 16 bis 18 zur Quantifizierung der Proteinexpression.
20. Verfahren nach einem der vorhergehenden Ansprüche, wobei das elektrochemische Verfahren Voltametrie ist.
- 40 21. Verfahren nach einem der Ansprüche 1 bis 19, wobei die elektrochemische Technik eine amperometrische Technik ist.
22. Verfahren nach Anspruch 20, wobei das Verfahren, das eingesetzt wird, die differentielle Pulsvoltametrie ist.
- 45 23. Verwendung eines Verfahrens, wie in einem vorhergehenden Anspruch beansprucht bei der Detektion eines genetischen Krankheit oder einer genetischen Krankheitsträgerstatus oder einer genetischen Prädisposition zur Erkrankung.
24. Verwendung eines Verfahrens nach einem der Ansprüche 1 bis 22 zur Detektion oder Identifikation eines Pathogens in einer Probe.  
50
25. Verwendung eines Verfahrens nach einem der Ansprüche 1 bis 22, zur Vorhersage der Resonanz eines Organismus auf ein therapeutisches oder toxisches Mittel.
- 55 26. Verwendung eines Nukleinsäuresondenmoleküls umfassend ein Oligonukleotid mit spezifischer Sequenz, das covalent an ein oder mehrere elektrochemisch aktive Markerreste gebunden ist, in einem Verfahren nach einem der Ansprüche 1 bis 22.
27. Verwendung nach Anspruch 26, wobei ein elektrochemisch aktiver Marker an das 3' Ende der Oligonukleotidsonde

gebunden ist.

28. Verwendung nach einem der Ansprüche 26 bis 27, wobei ein elektrochemisch aktiver Marker an das 5' Ende der Oligonukleotidsonde gebunden ist.
29. Verwendung nach einem der Ansprüche 26 bis 28, wobei multiple elektrochemisch aktive Marker entlang der Länge der Oligonukleotidsonde gebunden sind.
30. Verwendung nach einem der Ansprüche 26 bis 29, wobei ein elektrochemisch aktiver Marker an im Wesentlichen alle der Nukleotidreste der Oligonukleotidsonde gebunden ist.
31. Verwendung nach einem der Ansprüche 26 bis 29, wobei einer von mehreren elektrochemisch aktiven Markerresten den Formeln I, II, III, IV, VII oder VIII entspricht.
32. Verwendung nach einem der Ansprüche 26 bis 29, wobei die Oligonukleotidkomponente sowohl am 3' und als auch 5' Ende phosphoryliert ist.
33. Vorrichtung, die angeordnet ist, um ein oder mehrere Verfahrensansprüche 1 bis 22 auszuführen, aufweisend ein oder mehrere Proben aufnehmende Regionen zur Aufnahme ein oder mehrerer Proben, wobei die Vorrichtung einen Thermozykler aufweist und die Vorrichtung eine Vorrichtung für die Voltammetrie umfasst.
34. Ein Verfahren nach einem der Ansprüche 1 bis 22, bei welchem zwei oder mehrere Oligonukleotidsonden eingesetzt werden, wobei jede Sonde mit einem unterschiedlichen elektrochemisch aktiven Marker markiert ist.
35. Verfahren nach Anspruch 34, wobei die zwei oder mehr elektrochemisch aktive Marker Peaks in ihrem Voltammogramm aufweisen, die voneinander auflösbar sind.

#### Revendications

1. Procédé de sondage pour un acide nucléique comprenant : la mise en contact d'une solution d'acides nucléiques avec une sonde oligonucléotidique marquée avec un marqueur actif du point de vue électrochimique, la fourniture de conditions dans lesquelles la sonde est capable de s'hybrider au moins partiellement avec toute séquence cible complémentaire qui peut être présente dans la solution d'acides nucléiques, la dégradation sélective de la sonde à acide nucléique hybridée, partiellement hybridée, ou non hybridée, et la détermination par voie électrochimique d'informations concernant le marqueur actif du point de vue électrochimique.
2. Procédé selon la revendication 1, dans lequel les informations concernant le marqueur sont utilisées pour en déduire des informations concernant la présence ou l'absence d'au moins une espèce d'acide nucléique.
3. Procédé selon la revendication 1 ou la revendication 2, dans lequel la technique électrochimique est utilisée pour quantifier les proportions relatives de sonde dégradée et de sonde non dégradée.
4. Procédé selon l'une quelconque des revendications 1 à 3, dans lequel la sonde à acide nucléique qui n'a pas réussi à s'hybrider avec succès est digérée par une enzyme qui a été choisie pour digérer sélectivement un acide nucléique non hybridé monocaténaire.
5. Procédé selon l'une quelconque des revendications 1 à 3, dans lequel la sonde à acide nucléique qui s'est hybridée avec succès est digérée par une enzyme qui a été choisie pour digérer sélectivement au moins un brin d'acide nucléique hybridé bicaténaire.
6. Procédé selon la revendication 5, dans lequel l'enzyme est une 5'-nucléase.
7. Procédé selon la revendication 6, dans lequel la 5'-nucléase est aussi une ADN polymérase.
8. Procédé selon la revendication 7, dans lequel la 5'-nucléase/ADN polymérase est une enzyme thermostable.
9. Procédé selon la revendication 8, dans lequel l'enzyme thermostable est une Taq polymérase.

10. Procédé selon la revendication 8 ou la revendication 9, dans lequel le mélange réactionnel comprend aussi une paire d'amorces convenables pour l'élongation par l'ADN polymérase.
- 5 11. Procédé selon la revendication 10, dans lequel les conditions de réaction et le cyclage de température conviennent pour qu'une amplification en chaîne par polymérase (PCR) ait lieu en même temps que la digestion de la sonde par la 5'-nucléase.
- 10 12. Procédé selon l'une quelconque des revendications 1 à 3, dans lequel on empêche une première sonde oligonucléotidique marquée avec un marqueur actif du point de vue électrochimique de s'hybrider complètement par compétition avec un second oligonucléotide et l'oligonucléotide partiellement hybridé résultant marqué avec un marqueur actif du point de vue électrochimique est clivé par une enzyme qui reconnaît spécifiquement la configuration des deux oligonucléotides hybridés sur l'acide nucléique cible, ledit clivage raccourcissant effectivement la partie d'oligonucléotide à laquelle est attaché le marqueur actif du point de vue électrochimique.
- 15 13. Procédé selon l'une quelconque des revendications 1 à 3, dans lequel on empêche une première sonde oligonucléotidique de s'hybrider complètement par compétition avec un second oligonucléotide et la première sonde oligonucléotidique partiellement hybridée résultante est clivée par une enzyme qui reconnaît spécifiquement la configuration des deux oligonucléotides hybridés sur l'acide nucléique cible, le produit de clivage étant reconnu par une cassette de reconnaissance qui comprend au moins un oligonucléotide et est capable de s'hybrider au premier produit de clivage pour produire une configuration d'oligonucléotides reconnaissable par une enzyme qui clive une région de la cassette de reconnaissance qui est marquée avec un marqueur actif du point de vue électrochimique.
- 20 14. Procédé selon l'une quelconque des revendications précédentes pour la détection de polymorphismes d'acides nucléiques.
- 25 15. Procédé selon l'une quelconque des revendications 1 à 13 pour la quantification d'espèces d'acides nucléiques.
- 30 16. Procédé de détection d'une protéine ou d'un groupe de protéines spécifiques, comprenant : la mise en contact d'une solution de protéines avec une sonde oligonucléotidique marquée avec un marqueur actif du point de vue électrochimique, la fourniture de conditions dans lesquelles la sonde est capable de se lier à toute protéine ou tout groupe de protéines spécifiques qui peuvent être présents dans la solution, la dégradation sélective de la sonde à acide nucléique non hybridée, et la détermination par voie électrochimique d'informations concernant le marqueur actif du point de vue électrochimique afin de fournir des informations concernant la présence, l'absence ou les quantités absolues ou relatives de la protéine cible ou du groupe de protéines cibles spécifiques présents dans ladite solution.
- 35 17. Procédé selon la revendication 16, dans lequel l'acide nucléique non hybridé est dégradé par une enzyme.
- 40 18. Procédé selon la revendication 16 ou la revendication 17 pour la détection de polymorphismes de protéines.
19. Procédé selon l'une quelconque des revendications 16 à 18, pour la quantification de l'expression de protéines.
20. Procédé selon l'une quelconque des revendications précédentes, dans lequel le procédé électrochimique est la voltamétrie.
- 45 21. Procédé selon l'une quelconque des revendications 1 à 19, dans lequel la technique électrochimique est une technique ampérométrique.
22. Procédé selon la revendication 20, dans lequel le procédé utilisé est une voltamétrie pulsée différentielle.
- 50 23. Utilisation d'un procédé selon l'une quelconque des revendications précédentes dans la détection d'une maladie génétique ou d'un état de porteur de maladie génétique ou d'une prédisposition génétique à une maladie.
24. Utilisation d'un procédé selon l'une quelconque des revendications 1 à 22 pour détecter ou identifier un agent pathogène dans un échantillon.
- 55 25. Utilisation d'un procédé selon l'une quelconque des revendications 1 à 22 pour prédire une réponse d'un organisme à un agent thérapeutique ou toxique.

26. Utilisation d'une molécule sonde à acide nucléique comprenant un oligonucléotide de séquence spécifique lié de manière covalente à un ou plusieurs groupements de marqueur actif du point de vue électrochimique dans un procédé selon l'une quelconque des revendications 1 à 22.
- 5 27. Utilisation selon la revendication 26, dans laquelle un marqueur actif du point de vue électrochimique est attaché à l'extrémité 3' de la sonde oligonucléotidique.
28. Utilisation selon l'une quelconque des revendications 26 à 27, dans laquelle un marqueur actif du point de vue électrochimique est attaché à l'extrémité 5' de la sonde oligonucléotidique.
- 10 29. Utilisation selon l'une quelconque des revendications 26 à 28, dans laquelle plusieurs marqueurs actifs du point de vue électrochimique sont attachés le long de la sonde oligonucléotidique.
30. Utilisation selon l'une quelconque des revendications 26 à 29, dans laquelle un marqueur actif du point de vue électrochimique est attaché à pratiquement la totalité des résidus nucléotidiques de la sonde oligonucléotidique.
- 15 31. Utilisation selon l'une quelconque des revendications 26 à 29, dans laquelle un ou plusieurs groupements de marqueur actif du point de vue électrochimique correspondent aux formules I, II, III, IV, VII ou VIII.
- 20 32. Utilisation selon l'une quelconque des revendications 26 à 29, dans laquelle le composant oligonucléotidique est phosphorylé au niveau des deux extrémités 3' et 5'.
33. Appareil disposé pour mettre en oeuvre des procédés selon l'une quelconque ou plusieurs des revendications 1 à 22 comprenant une ou plusieurs régions réceptrices d'échantillon pour recevoir un ou plusieurs échantillons, dans lequel l'appareil comprend un cycleur thermique et l'appareil comprend un dispositif pour voltamétrie.
- 25 34. Procédé selon l'une quelconque des revendications 1 à 22, dans lequel deux ou plusieurs sondes oligonucléotidiques sont utilisées, chaque sonde étant marquée avec un marqueur actif du point de vue électrochimique différent.
- 30 35. Procédé selon la revendication 34, dans lequel les deux ou plusieurs marqueurs actifs du point de vue électrochimique présentent des pics dans leur tracé de voltamogramme qui peuvent être séparés l'un de l'autre.

35

40

45

50

55




Fig. 1




Fig. 2a




Fig. 2b






Fig. 2c




Fig. 2d




Fig. 3a




Fig. 3b




Fig. 3c




Fig. 3d




Fig. 4a






Fig. 4b






Fig. 5a




Fig. 5b




Fig. 5c




Fig. 5d




Fig. 6a




Fig. 6b






Fig. 6c




Fig. 6d




Fig. 7a




Fig. 7b




Fig. 7c




Fig. 7d




Fig. 8a




Fig. 8b




Fig. 9a




Fig. 9b




Fig. 10a




Fig. 10b




Fig. 10c




Fig. 10d




Fig. 11a




Fig. 11b






Fig. 11c




Fig. 12a




Fig. 12b

$E/V$




Fig. 12c






Fig. 12d






Fig. 13c




Fig. 13d




Fig. 14a




Fig. 14 b




Fig. 15a




Fig. 15b

Fig. 15






Fig. 16a




Fig 16b




Fig. 17a




Fig. 17b




Fig. 18a




Fig. 18b




Fig. 18c




Fig. 18d




Fig. 19a




Fig. 19b




Fig. 20a




Fig. 20b




Fig. 21a




Fig. 21b




Fig. 22a




Fig. 22b






Figure 23(a)




Figure 23(b)




Figure 23(c)






Figure 23(d)






Figure 24(c)

$E/V$